Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia

Bone Marrow Transplantation

Volumn 49, Issue 8, 2014, Pages 1116-1118

  Okano, M ^a   Sakata, N ^a   Ueda, S ^a   Takemura, T ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

ALLOGRAFT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; HUMAN; MALE; THROMBOTIC MICROANGIOPATHIES;

ALLOGRAFTS; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE MARROW TRANSPLANTATION; CHILD; HUMANS; MALE; THROMBOTIC MICROANGIOPATHIES;

EID: 84905676449     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.97     Document Type: Letter

References (8)

1. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575.
2. Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-531.
3. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009; 69: 183-198.
4. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003-2007.
5. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med 2004; 350: 552-559.
6. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 2013; 61: 289-299.
7. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013; 161: 279-280.
8. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379-387